Several genetic variations have been demonstrated to modulate the efficacy of tocilizumab in RA, for example in FCGR3A, IL6R, CD69, and GALNT18 genes, therefore, the same can apply to the treatment of COVID-19 patients [109,110,111]. Here, GALNT18 is linked to rheumatoid arthritis.